

**Revised Draft Agenda**  
**Biocides Working Group Meeting I-2021**  
**15-25 March 2021**

**WG-I-2021 meetings are held as virtual meetings via WebEx**

The time is indicated in Helsinki time.

Mon 15 March	10:00-17:00	APCP WG
Tue 16 March	10:00-17:00	APCP WG
Wed 17 March	10:00-17:00	APCP WG
Tue 16 March	10:00-17:00	TOX WG
Wed 17 March	10:00-17:00	TOX WG
Thu 18 March	10:00-17:00	TOX WG
Thu 18 March	10:00-17:00	EFF WG
Tue 23 March	10:00-17:00	EFF WG
Thu 25 March	10:00-17:00	EFF WG
Wed 24 March	10:00-17:00	ENV WG
Thu 25 March	10:00-17:00	ENV WG

<b>Analytical methods and physico-chemical properties Working Group</b>		
<b>Chair: Bernhard Krebs</b>		
<b>Item 1 - Welcome and apologies</b>		
<b>Item 2 – Administrative issues</b>		
<b>Item 3 – Agreement of the agenda</b>		<i>For agreement</i>
<b>Item 4 – Declarations of potential conflicts of interest in relation to the agenda</b>		
<b>Item 5 – Agreement of the draft minutes of WG IV 2020</b> <i>WG IV 2020_APCP_6-1</i> <i>WG IV 2020_APCP_Gen agenda items</i>		<i>For agreement</i>
<b>Item 6 – Training (closed session)</b>		
<b>Item 7 – Outcome of e-consultations (closed session)</b>		
<b>Item 8 - Discussion of Active Substances</b>		<b>eCA</b>
<b>8.1</b>	<b>L-(+)-lactic acid</b> PT 06 Meeting document: <i>WGI 2021_APCP_8-1</i>	DE  <i>For agreement</i>
<b>Item 9 - Discussion of Union Authorisations</b>		<b>eCA</b>
<b>9.1</b>	<b>UA for product containing Permethrin</b> PT 18 (BC-GK024706-40) Meeting document: <i>WGI 2021_APCP_9-1</i>	DK  <i>For agreement</i>
<b>9.2</b>	<b>UA for product containing active chlorine released from chlorine</b> PT 02, 05 (BC-UQ045679-98) Meeting document: <i>WGI 2021_APCP_9-2</i>	BE  <i>For agreement</i>
<b>9.3</b>	<b>UA for product containing active chlorine released from sodium hypochlorite</b> PT 02 (BC-ER045796-14) Meeting document: <i>WGI 2021_APCP_9-3</i>	BE  <i>For agreement</i>
<b>Item 10 - Technical and guidance related issues</b>		
<b>Item 11 – AOB</b>		

<b>Human Health Working Group</b>		
<b>Chair: Antero Airaksinen</b>		
<b>Item 1 - Welcome and apologies</b>		
<b>Item 2 – Administrative issues</b>		
<b>Item 3 – Agreement of the agenda</b>		<i>For agreement</i>
<b>Item 4 – Declarations of potential conflicts of interest in relation to the agenda</b>		
<b>Item 5 – Agreement of the draft minutes from WG-IV-2020</b>		
<ul style="list-style-type: none"> <li>• WG-IV-2020_TOX_6-1</li> <li>• WG-IV-2020_TOX_6-2</li> <li>• WG-IV-2020_TOX_7-1</li> <li>• WG-IV-2020_TOX_Minutes</li> </ul>		<i>For agreement</i>
<b>Item 6 - Discussion of Active Substances</b>		<b>eCA</b>
<b>6.1</b>	<b>L-(+)-lactic acid</b> PT 6 Meeting document: <i>WGI2021_TOX_6-1</i>	DE
<i>For agreement</i>		
<b>6.2</b>	<b>Sulfur dioxide released from sodium metabisulfite – ED Assessment</b> PT 9 Meeting documents: <i>WGI2021_TOX_6-2</i>	DE
<i>For agreement</i>		
<b>Item 7 - Discussion of Union Authorisations</b>		<b>eCA</b>
<b>7.1</b>	<b>UA for product containing Permethrin</b> PT 18 (BC-GK024706-40) Meeting document: <i>WGI2021_TOX_7-1</i>	DK
<i>For agreement</i>		
<b>7.2</b>	<b>UA for product containing active chlorine released from chlorine</b> PT 2, 5 (BC-UQ045679-98) Meeting document: <i>WGI2021_TOX_7-2</i>	BE
<i>For agreement</i>		

<b>7.3</b>	<b>UA for product containing active chlorine released from sodium hypochlorite</b> PT 2 (BC-ER045796-14) Meeting document: <i>WGI2021_TOX_7-3</i> <i>For agreement</i>	BE
<b>Item 8 – Discussion of mutual recognition</b>		<b>RefMS</b>
<b>8.1</b>	<b>Request to ECHA for an opinion pursuant to Articles 36(2) and 38 of the BPR</b> Meeting document: <i>WGI2021_TOX_8-1</i> <i>For agreement</i>	FR
<b>Item 9 - Technical and guidance related issues</b>		<b>Presenter</b>
<b>9.1</b>	<b>Update on guidance development</b> Meeting document: <i>WGI2021_TOX_9-1</i> <i>For discussion</i>	SECR
<b>9.2</b>	<b>Proposal for a new TAB entry on local effects</b> Meeting document: <i>WGI2021_TOX_9-2</i> <i>For agreement</i>	DE
<b>9.3</b>	<b>Review of TAB</b> Meeting document: <i>WGI2021_TOX_9-3</i> <i>For agreement</i>	SECR
<b>9.4</b>	<b>Dermal absorption of rodenticides</b> Meeting document: <i>WGI2021_TOX_9-4</i> <i>For agreement</i>	DE
<b>Item 10 – AOB</b>		<b>Presenter</b>
<b>10.1</b>	<b>Other information &amp; lessons learned</b> Meeting document: <i>WGI2021_TOX_10-1</i> <i>For discussion</i>	SECR
<b>10.2</b>	<b>Meeting the timelines: alternative ways of working</b> Meeting document: <i>WGI2021_TOX_10-2</i> <i>For discussion</i>	SECR

<b>Environment Working Group</b> <b>Chair: Heike Schimmelpfennig</b>		
<b>Item 1 - Welcome and apologies</b>		
<b>Item 2 – Administrative issues</b>		
<b>Item 3 – Agreement of the agenda</b>		<i>For agreement</i>
<b>Item 4 – Declarations of potential conflicts of interest in relation to the agenda</b>		
<b>Item 5 – Agreement of the draft minutes of WG-IV-2020</b>		
<ul style="list-style-type: none"> <li>• WG-IV-2020_ENV_6-1</li> <li>• WG-IV-2020_ENV_6-2</li> <li>• WG-IV-2020_ENV_7-1</li> <li>• WG-IV-2020_ENV_General_minutes</li> </ul>		<i>For agreement</i>
<b>Item 6 - Discussion of Active Substances</b>		<b>eCA</b>
<b>6.1</b>	<b>L-(+)-lactic acid</b> PT 06 Meeting document: <i>WGI2021_ENV_6-1</i>	DE
<i>For agreement</i>		
<b>6.2</b>	<b>Post-approval data for OIT</b> PT 06, 07, 09, 10, 11 and 13 + PT 08 submission to BPC Meeting document: <i>WGI2021_ENV_6-2</i>	FR
<i>For agreement</i>		
<b>Item 7 - Discussion of Union Authorisations</b>		<b>eCA</b>
<b>7.1</b>	<b>UA for product containing Permethrin</b> PT 18 (BC-GK024706-40) Meeting document: <i>WGI2021_ENV_7-1</i>	DK
<i>For agreement</i>		
<b>7.2</b>	<b>UA for product containing active chlorine released from chlorine</b> PT 02, 05 (BC-UQ045679-98) Meeting document: <i>WGI2021_ENV_7-2</i>	BE
<i>For agreement</i>		

<b>7.3</b>	<b>UA for product containing active chlorine released from sodium hypochlorite</b> PT 02 (BC-ER045796-14) Meeting document: <i>WGI2021_ENV_7-3</i> <i>For agreement</i>	BE
<b>Item 8 – Technical and guidance related issues</b>		<b>Presenter</b>
<b>8.1</b>	<b>Overview on guidance</b> Meeting document: <i>WGI2021_ENV_8-1</i> <i>For information</i>	SECR
<b>8.2</b>	<b>TAB database entries - open questions</b> Meeting document: <i>WGI2021_ENV_8-2</i> <i>For agreement</i>	SECR
<b>8.3</b>	<b>Development of Chesar platform – status and open questions</b> Meeting document: <i>WGI2021_ENV_8-3</i> <i>For information/agreement</i>	SECR
<b>8.4</b>	<b>CEPE study: semi-field leaching tests for PT 7</b> CEPE to inform <i>For information</i>	CEPE
<b>8.5</b>	<b>Outcome of recent case-specific e-consultations</b> Meeting document: <i>WGI2021_ENV_8-5</i> <i>For agreement</i>	SECR, DE
<b>8.6</b>	<b>Guidance on Pollinators-Status update</b> SECR to inform <i>For information</i>	SECR
<b>Item 9 – AOB</b>		
<b>9.1</b>	<b>Other information &amp; lessons learned</b> SECR to inform <i>For information</i>	SECR
<b>9.2</b>	<b>Meeting the timelines: alternative ways of working</b> Meeting document: <i>WGI2021_ENV_9-2</i> <i>For discussion</i>	SECR

<b>Efficacy Working Group</b>		
<b>Chair: Katarzyna Szymankiewicz</b>		
<b>Item 1 - Welcome and apologies</b>		
<b>Item 2 – Administrative issues</b>		
<b>Item 3 – Agreement of the agenda</b>		<i>For agreement</i>
<b>Item 4 – Declarations of potential conflicts of interest in relation to the agenda</b>		
<b>Item 5 – Agreement of the draft minutes from WG-IV-2020</b>		
<ul style="list-style-type: none"> <li>• WG-IV-2020_EFF_6-1</li> <li>• WG-IV-2020_EFF_7-1</li> <li>• WG-IV-2020_EFF_Minutes</li> </ul>		<i>For agreement</i>
<b>Item 6 – Discussion of Active Substances</b>		<b>eCA</b>
<b>6.1</b>	<b>L-(+)-lactic acid</b> PT 06 Meeting document: <i>WGI2021_EFF_6-1</i>	DE
		<i>For agreement</i>
<b>Item 7 - Discussion of Union Authorisations</b>		<b>eCA</b>
<b>7.1</b>	<b>UA for product containing Permethrin</b> PT 18 (BC-GK024706-40) Meeting document: <i>WGI2021_EFF_7-1</i>	DK
		<i>For agreement</i>
<b>7.2</b>	<b>UA for product containing active chlorine released from chlorine</b> PT 02, 05 (BC-UQ045679-98) Meeting document: <i>WGI2021_EFF_7-2</i>	BE
		<i>For agreement</i>
<b>7.3</b>	<b>UA for product containing active chlorine released from sodium hypochlorite</b> PT 02 (BC-ER045796-14) Meeting document: <i>WGI2021_EFF_7-3</i>	BE
		<i>For agreement</i>

<b>7.4</b>	<b>Early WG on UA-APP containing Margosa extract from cold-pressed oil of the kernels of Azadirachta Indica extracted with super-critical carbon dioxide</b> PT 19 (BC-TV050221-21) Meeting document: <i>WGI2021_EFF_7-4</i> <i>For agreement</i>	FR
<b>Item 8 - Technical and guidance related issues</b>		
<b>8.1</b>	<b>Vol. II, Parts B+C – PT1-5</b> Meeting document: <i>WGI2021_EFF_8-1</i> <i>For discussion</i>	ECHA
<b>8.2</b>	<b>TAB proposals</b> <ul style="list-style-type: none"> <li>• <b>PT14: Efficacy requirements for products with a lowered active substance concentration</b> Meeting document: <i>WGI2021_EFF_8-2a</i></li> <li>• <b>PT18: Crack and crevice treatment test (closed session)</b> Meeting document: <i>WGI2021_EFF_8-2b</i></li> </ul> <i>For discussion</i>	DE/NL
<b>8.3</b>	<b>Resistance assessment guidance of biocidal antimicrobial active substances and products</b> Meeting document: <i>WGI2021_EFF_8-3</i> <i>For discussion</i>	FR
<b>8.4</b>	<b>Requirements for insecticide and repellent treated articles</b> Meeting document: <i>WGI2021_EFF_8-4</i> <i>For information</i>	SE
<b>Item 9 – AOB</b>		
<b>9.1</b>	<b>Other information &amp; lessons learned</b> Meeting document: <i>WGI2021_EFF_9-1</i> <i>For information</i>	ECHA
<b>9.2</b>	<b>Meeting the timelines: alternative ways of working (closed session)</b> Meeting document: <i>WGI2021_EFF_9-2</i> <i>For discussion</i>	ECHA